Abstract:Our study indicated that the 14‐gene‐related prognostic signature gene could serve as a novel biomarker for predicting breast cancer patients' prognosis. We found that immunotherapy might play a vital role in therapeutic schedule based on the level and difference of immune‐related cells and pathways in different risk groups. Background Breast cancer (BC), a malignant tumor, is a significant cause of death and disability among women globally. Recent research indicates that copy number variation plays a crucial role in tumor development. In this study, we employed the Single‐Cell Variational Aneuploidy Analysis (SCEVAN) algorithm to differentiate between malignant and non‐malignant cells, aiming to identify genetic signatures with prognostic relevance for predicting patient survival. Methods We analyzed gene expression profiles and associated clinical data from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases. Using the SCEVAN algorithm, we distinguished malignant from non‐malignant cells and investigated cellular interactions within the tumor microenvironment (TME). We categorized TCGA samples based on differentially expressed genes (DEGs) between these cell types. Subsequent Kyoto Encyclopedia of Genes and Genomes pathway analysis was conducted. Additionally, we developed polygenic models for the DEGs using least absolute shrinkage and selection operator‐penalized Cox regression analysis. To assess the prognostic accuracy of these characteristics, we generated Kaplan–Meier and receiver operating characteristic curves from training and validation datasets. We also monitored the expression variations of prognostic genes across the pseudotime of malignant cells. Patients were divided into high‐risk and low‐risk groups based on median risk scores to compare their TME and identify potential therapeutic agents. Lastly, polymerase chain reaction was used to validate seven pivotal genes. Results The SCEVAN algorithm identified distinct malignant and non‐malignant cells in GSE180286. Cellchat analysis revealed significantly increased cellular communication, particularly between fibroblasts, endothelial cells and malignant cells. The DEGs were predominantly involved in immune‐related pathways. TCGA samples were classified into clusters A and B based on these genes. Cluster A, enriched in immune pathways, was associated with poorer prognosis, whereas cluster B, predominantly involved in circadian rhythm pathways, showed better outcomes. We constructed a 14‐gene prognostic signature, validated in a 1:1 internal TCGA cohort and external GEO datasets (GSE42568 and GSE146558). Kaplan–Meier analysis confirmed the prognostic signature's accuracy (p

A novel investigation into an E2F transcription factor‐related prognostic model with seven signatures for colon cancer patients

Application of RNA Processing Factors for Predicting Clinical Outcomes in Colon Cancer.

A Novel Coiled-Coil Domain Containing-Related Gene Signature for Predicting Prognosis and Treatment Effect of Breast Cancer.

A Novel Transcription Factor-Based Prognostic Signature in Endometrial Cancer: Establishment and Validation.

Development and Validation of a Prognostic Model based on 11 E3-related Genes for Colon Cancer Patients

Association of a novel seven-gene expression signature with the disease prognosis in colon cancer patients

A new prognostic signature of 11 E3-related genes for colon cancer related to the immune microenvironment and somatic mutation

Integrative analysis reveals a four-gene signature for predicting survival and immunotherapy response in colon cancer patients using bulk and single-cell RNA-seq data

Identification and validation of a seven‐gene prognostic marker in colon cancer based on single‐cell transcriptome analysis

Identification of Transcription Factor-Related Gene Signature and Risk Score Model for Colon Adenocarcinoma.

A bioinformatics analysis for diagnostic roles of the E2F family in esophageal cancer

Construction of a Prognostic Model for Colon Cancer by Combining Endoplasmic Reticulum Stress Responsive Genes

Identification of cuproptosis and ferroptosis-related subtypes and development of a prognostic signature in colon cancer

A novel prognostic model based on multi‐omics features predicts the prognosis of colon cancer patients

Identification and Validation of a Novel DNA Damage and DNA Repair Related Genes Based Signature for Colon Cancer Prognosis

A Novel Epithelial-Mesenchymal Transition Molecular Signature Predicts The Oncological Outcomes In Colorectal Cancer

A novel enterocyte-related 4-gene signature for predicting prognosis in colon adenocarcinoma

Identification of a novel prognostic signature composed of 3 cuproptosis-related transcription factors in colon adenocarcinoma

Development of a novel prognostic signature based on single‐cell combined bulk RNA analysis in breast cancer

Development and Validation of an E2F-Related Gene Signature to Predict Prognosis of Patients with Lung Squamous Cell Carcinoma

Identification of Distinct Molecular Patterns and a Four-Gene Signature in Colon Cancer Based on Invasion-Related Genes